NOTE 12 - SUBSEQUENT EVENTS | A. | Through January and February, 2014 the Company received approximately $380 from the Chief Scientist of the State of Israel for participation in research and development. | | B. | In March 2014, the Company signed a definitive agreement with the Massachusetts General Hospital (MGH) in Boston, MA to conduct a Phase II clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS), pending FDA approval. | |